AI assistant
Editas Medicine, Inc. — Director's Dealing 2026
Mar 4, 2026
33260_dirs_2026-03-04_2d8e458e-1040-4d46-91ba-7ebdfdee2ad0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2026-03-03
Reporting Person: O'Neill Gilmore Neil (Director, CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-03-03 | Common Stock | S | 5394 | $2.0197 | Disposed | 263693 | Direct |
Footnotes
F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
F2: This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204 The price reported above reflects the weighted average purchase price. The Reporting Person hereby
undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.